Newsroom
April 19, 2022
Thanks to international collaboration, more genetic variations for Alzheimer’s disease are known today than ever before. The list of gene variants recognized for late-onset Alzheimer’s grew from one in 2009 to 40 in 2022. This month, scientists published a list of 75, some of which are considered as prime drug targets. Drug development is underway. […]
April 14, 2022
Researchers from UT Health San Antonio today reported the discovery of a novel mechanism by which pathological forms of tau protein cause neurons to die. Alzheimer’s disease and chronic traumatic encephalopathy (CTE) are among more than 20 disorders that include tau protein pathology. The newly found mechanism of tau-induced damage can be altered pharmacologically, the scientists noted, making it a novel target for drug development.
April 13, 2022
mRNA quality control identified as novel drug target for Alzheimer’s and related dementias Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (April 13, 2022) — Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) today reported the discovery of a novel mechanism by which pathological forms of tau […]
February 24, 2022
Latino voices to shape new studies to improve care, support for families living with dementia South Texas Latinos will have the opportunity to share the challenges and concerns of living with dementia and caring for individuals affected by dementia through a new project of The University of Texas Health Science Center at San Antonio, also […]
February 3, 2022
Dr. Alexander Papanastassiou, Neurosurgery, and Dr. Gabriel de Erausquin, Neurology/Glenn Biggs Institute, are quoted in this story. Read More
February 1, 2022
UT Health San Antonio and clinical partner University Health are among 27 sites worldwide evaluating the effectiveness of a technique called deep brain stimulation in treating patients with mild Alzheimer’s disease.
